home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Oncogenes And Sensitivity To Anti-Cancer-Drugs

 
  November, 2 2000 1:49
your information resource in human molecular genetics
 
     
Oncogenes are genes that drive so-called 'transformed cells' to excess proliferation when they are deregulated and overexpressed. The expression of oncogenes sensitizes transformed cells to drugs (as compared with normal cells) and such drugs can thus be used to prevent cellular proliferation and hence be used for cancer therapy. Understanding the rationale behind the different sensitivity to anti-cancer drugs of transformed cells versus normal cells may provide new strategies to selectively destroy tumour cells.

There are two possible explanations to account for the differential sensitivity to anti-cancer drugs of transformed cells versus normal cells: either the expression of oncogenes 'actively' predispose cells to apoptosis (cell death), or normal cells are intrinsically protected from apoptosis and oncogenes somehow overcome this protection. Yuri Lazebnik and his colleagues at Cold Spring Harbor Laboratory, NY, now provide evidence in favour of the latter hypothesis on pages 859-862 of the November issue of Nature Cell Biology. They tackle the problem by generating a fusion between transformed cells expressing the adenoviral E1A oncogene and normal cells. If it is transformed cells that 'actively' drive the cells towards death, then the product of the fusion (the heterocaryon) is expected to be sensitive to anti-cancer drugs. If, on the contrary, it is normal cells that provide an 'active' resistance cue, then the heterocaryon would be resistant to anti-cancer drugs. It turns out that the heterocaryon is indeed resistant to anti-cancer drugs. The authors checked that this was not due to trivial reasons such as dilution of the E1A oncogene. Thus, normal cells are intrinsically resistant to anti-cancer drugs and oncogenes somehow neutralize this protection pathway. Once we find out how this is achieved, which is what Yuri Lazebnik and his collaborators are currently working on, advantage could be taken of this specific 'weakness' of transformed cells in anti-cancer treatments.

CONTACT:
Yuri Lazebnik
tel + 1 516 367 8363
fax + 1 516 367 8461
e-mail lazebnik@cshl.org

(C) Nature Cell Biology press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.